Agios Pharmaceuticals (NASDAQ:AGIO) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Agios Pharmaceuticals (NASDAQ:AGIO) issued its earnings results on Thursday. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.09), Briefing.com reports. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 44.84%. The company had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. During the same quarter in the previous year, the company posted ($1.51) EPS. The company’s quarterly revenue was up 28.4% on a year-over-year basis.

Agios Pharmaceuticals Stock Performance

AGIO stock opened at $43.96 on Friday. Agios Pharmaceuticals has a one year low of $19.80 and a one year high of $50.35. The stock has a market capitalization of $2.50 billion, a PE ratio of -6.96 and a beta of 0.79. The company has a fifty day moving average of $44.48 and a 200-day moving average of $34.56.

Analyst Upgrades and Downgrades

AGIO has been the subject of a number of recent research reports. Royal Bank of Canada increased their price target on shares of Agios Pharmaceuticals from $53.00 to $55.00 and gave the stock an “outperform” rating in a research note on Friday. The Goldman Sachs Group increased their price target on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 4th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $46.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 17th. Finally, StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 11th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $51.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.